This clinical trial is focused on studying a condition known as IgG4-related disease (IgG4-RD). This is a rare condition where the immune system, which normally protects the body, mistakenly attacks healthy tissues, leading to inflammation and damage in various organs. The study is testing a treatment called inebilizumab, which is a type of medication known as a monoclonal antibody. Monoclonal antibodies are proteins made in a lab that can bind to specific targets in the body, in this case, to help reduce the immune system’s attack on healthy tissues.

The purpose of the study is to evaluate how effective inebilizumab is in reducing the risk of a disease flare, which is a sudden worsening of symptoms, in patients with IgG4-related disease. Participants in the study will receive either the medication or a placebo, and the study will follow them over a period to see how well the treatment works in preventing flares. The study is designed to be double-blind, meaning neither the participants nor the researchers know who is receiving the actual medication or the placebo, to ensure unbiased results.

Throughout the study, participants will receive regular check-ups and monitoring to assess their health and the effectiveness of the treatment. The study aims to provide valuable information on whether inebilizumab can be a safe and effective treatment option for managing IgG4-related disease and reducing the frequency of flares. This research could potentially lead to better treatment options for those affected by this condition.